Relax Group
HOLDProspects have improved for restructured debt management specialist Relax Group after a 17 per cent annual pre-tax profits fall to £2.78 million.
AIM-quoted Relax, formerly Debts.co.uk, increased revenue nearly 20 per cent to £13.8 million in the year to July. However, the company, which has been adding debt and arrears book management to individual voluntary arrangements (IVAs) in its business mix, also had to bear exceptional costs of £2.8 million involved in acquisitions and rationalisation and, after these and other exceptional items, showed pre-tax profits down from £3.4 million to a mere £14,000.
Acquisitions, chiefly Relax Finance and PB Recovery, had a strong impact on the second-half performance of Chesterfield-based Relax, which ended its financial year with cash reduced from £1.2 million to £886,000. With rationalisation benefits also showing through and demand for debt management plans, IVAs and other instruments on the rise, chief executive Paul Carter says 2009 ‘should exceed market expectations’ in a sector that is gaining from the economic recession. Analysts expect pre-tax profits up 50 per cent to £4.2 million in the year to next July.
Past travails in the IVA market (now mostly resolved) and internal issues knocked the shares of Debts.co.uk/Relax all the way from 219.5p in 2006 to 18p earlier this month. Recommended by Growth Company Investor at 24.5p in August and now trading at 23.5p, the shares are worth holding.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £7.2m
PE Forecast: 1.7
Share price: 23.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
